BRAF and melanoma: In addition to the complex decision between monotherapy and combination therapy, approximately half of patients have to consider yet another treatment option, as targeted therapy with BRAF and MEK inhibitors can also be used in the presence of a BRAF mutation (up to 50% of melanomas) [14–16].